

Table of Contents

List of Figures	XII
List of Tables	XVI
List of Abbreviation	XVII
Preface	XXII
1 Introduction	2
1.1 Epidemiology	3
1.2 Causes of multiple sclerosis	4
1.3 Clinical symptoms and diagnosis of MS	5
1.4 Animal models of multiple sclerosis	6
1.4.1 Mouse models of EAE.....	7
1.4.2 Rat models of EAE.....	8
1.4.3 Clinical comparison with EAE.....	8
1.4.4 Choice of autoantigen.....	9
1.4.5 Role of adjuvants.....	10
1.5 Treatment and prevention of multiple sclerosis	11
1.6 Limitations of current treatments of multiple sclerosis.....	11
1.7 Dimethyl fumarate.....	13
1.7.1 Limitations of Dimethyl fumarate	14
1.7.2 Cathepsin C as a novel target in multiple sclerosis	15
1.8 Cocrystals	15
1.9 Rationale.....	17
1.10 Objectives.....	18
2 Immunological mechanism of dimethyl fumarate in EAE model of multiple sclerosis	20
2.1 Introduction	20

2.2	Materials and methods	23
2.2.1	Chemicals.....	23
2.2.2	<i>In-vitro</i> experiment	23
2.2.3	Time dependent/ Irreversible enzyme kinetics and calculation of IC ₅₀ :.....	24
2.2.4	Reversibility Inhibition Studies	24
2.2.5	Experimental animals and drug treatment.....	24
2.2.6	Preparation of MOG ₃₅₋₅₅ emulsion in CFA.....	25
2.2.7	Preparation of Pertussis Toxin	26
2.2.8	EAE induction.....	26
2.2.9	Histopathology to assess demyelination:	27
2.2.10	Mononuclear cells isolation and preparation:	27
2.2.11	FACS analysis.....	28
2.2.12	Cathepsin C Activity	29
2.2.13	Granzyme B activity	29
2.2.14	Statistical Analysis.....	29
2.3	Results.....	30
2.3.1	Time dependent and irreversible enzyme kinetics and calculation of IC ₅₀	30
2.3.2	Reversibility inhibition studies of DMF and MMF with cathepsin C enzyme:	33
2.3.3	Effect of DMF on clinical scoring in MOG ₃₅₋₅₅ induced EAE mice	35
2.3.4	Effect of DMF on the migration of CD4 ⁺ and CD8 ⁺ T cells migration into CNS of MOG ₃₅₋₅₅ induced EAE mice.....	36
2.3.5	Effect of DMF on cathepsin C activity in MOG ₃₅₋₅₅ induced EAE mice	39
2.3.6	Effect of DMF on Granzyme B activity in MOG ₃₅₋₅₅ induced EAE mice.....	40
2.3.7	Effect of DMF on demyelination in MOG ₃₅₋₅₅ induced EAE mice	42
2.4	Summary	43
3	Preparation, characterization, <i>in-vitro</i> and <i>in-vivo</i> pharmacokinetic evaluation of dimethyl fumarate cocrystal with basic co-former (Nicotinamide)	45
3.1	Introduction.....	45

3.2	Materials and Methods	48
3.2.1	<i>In-silico</i> work.....	48
3.2.2	Molecular docking.....	48
3.2.3	Molecular dynamics	49
3.2.4	Experimental Animals	49
3.2.5	Materials	49
3.2.6	Method of Preparation.....	50
3.2.7	Formulation	50
3.3	Characterization of cocrystals	51
3.3.1	Attenuated total reflectance FTIR (ATR- FTIR) spectroscopy	51
3.3.2	Powder X-ray Diffraction (PXRD).....	51
3.3.3	Thermal stability evaluation of cocrystals.....	51
3.3.4	Differential Scanning Calorimetry (DSC).....	52
3.3.5	Thermogravimetric Analysis (TGA)	52
3.3.6	Evaluation of Sublimation behavior	52
3.3.7	Dissolution.....	53
3.3.8	HPLC analysis	53
3.4	<i>In vitro</i> evaluation of biological activity of cocrystals	54
3.4.1	Isolation of peripheral blood mononuclear cells (PBMCs)	54
3.4.2	PBMC counting via Trypan blue exclusion (TBE) assay.....	54
3.4.3	Cytotoxicity assay	54
3.4.4	Cytokine analysis.....	55
3.4.5	Measurement of intracellular ROS (iROS)	55
3.4.6	Pharmacokinetic study.....	56
3.4.7	Acute ulcer model of rat	57
3.4.8	Acetic acid-induced chronic gastric ulcers in rats	57
3.4.9	Evaluation of gross lesions on the gastric mucosa	58

3.4.10	Determination of related biochemical indexes in gastric tissues	58
3.4.11	Histopathology	59
3.4.12	Statistical analysis	59
3.5	Results.....	59
3.5.1	Molecular docking	59
3.5.2	Molecular dynamics.....	60
3.5.3	Characterization of DMF-NIC cocrystal by attenuated total reflectance FTIR (ATR-FTIR) 61	61
3.5.4	Characterization of DMF-NIC cocrystal by TGA.....	62
3.5.5	Characterization of DMF-NIC cocrystal by DSC.....	63
3.5.6	Characterization of DMF-NIC cocrystal using PXRD	64
3.5.7	Effect of cocrystallization on sublimation behaviour of DMF	65
3.5.8	Effect of cocrystallization on dissolution profile:	66
3.5.9	Pharmacokinetics of DMF and DMF-NIC cocrystal:	67
3.5.10	Cell viability assay	69
3.5.11	Effect of DMF-NIC cocrystal on oxidative stress.....	69
3.5.12	Effect of cocrystals on IL-6 activity.....	70
3.5.13	Effect of Cocrystals on TNF- α activity.....	71
3.5.14	Acute gastric acid model.....	72
3.5.15	Acetic acid induced gastric healing.....	73
3.5.16	Acetic acid induced gastric healing by MDA activity	74
3.5.17	Total Nitrite level.....	76
3.6	Summary.....	77
4	Preparation, characterization, in-vitro and in-vivo pharmacokinetic evaluation of dimethyl fumarate cocrystals with acid-based cofomers Preparation, characterization, in-vitro and in-vivo pharmacokinetic evaluation of dimethyl fumarate cocrystals with acid-based cofomers	79
4.1	Introduction.....	80
4.2	Materials and methods	83

4.2.1	Molecular docking.....	83
4.2.2	Molecular dynamics	83
4.2.3	Experimental animals	84
4.3	Materials.....	84
4.3.1	Method of preparation	84
4.3.2	Attenuated total reflectance FTIR (ATR- FTIR) spectroscopy.....	85
4.3.3	Powder X-ray Diffraction (PXRD).....	85
4.3.4	Thermal analysis.....	85
4.3.5	Differential Scanning Calorimetry (DSC).....	86
4.3.6	Thermogravimetric Analysis (TGA)	86
4.3.7	Evaluation of Sublimation behavior	86
4.3.8	<i>In-vitro</i> dissolution study.....	87
4.3.9	Quantification of the drug in prepared cocrystals.....	87
4.3.10	Isolation and counting of peripheral blood mononuclear cells (PBMCs)	88
4.3.11	Cytotoxicity assay	88
4.3.12	Cytokine analysis.....	89
4.3.13	Measurement of intracellular ROS (i-ROS)	89
4.3.14	Pharmacokinetic study.....	90
4.3.15	Statistical analysis	91
4.4	Result and discussion	91
4.4.1	Molecular docking.....	91
4.4.2	Molecular dynamics	92
4.4.3	Formulation of cocrystals.....	94
4.4.4	Attenuated total reflectance FTIR (ATR- FTIR) spectroscopy.....	94
4.4.5	Characterization of cocrystals by TGA	96
4.4.6	Characterization of cocrystals by DSC.....	97
4.4.7	Characterization of cocrystals by PXRD.....	99

4.4.8	Effect of cocrystallization on sublimation behavior of DMF	101
4.4.9	Dissolution	102
4.4.10	Pharmacokinetics of DMF and its cocrystals.....	103
4.4.11	Cell viability assay	105
4.4.12	ROS activity: DCF Assay	106
4.4.13	Effect of cocrystals on IL-6 activity.....	107
4.4.14	Effect of cocrystals on TNF- α activity.....	109
4.5	Discussion	110
4.6	Summary	113
5	Summary & Conclusion.....	115
5.1	Important outcomes	117
5.2	Future studies	117
5.3	Impact on the treatment of multiple sclerosis	118
6	References.....	120